MYC and plasma cell myeloma: Fedratinib potently suppressed c-Myc expression (a well-established marker of BET inhibition) in MM.1S multiple myeloma cells; in contrast, c-Myc was not suppressed by selective JAK inhibitors that lacked BET activity, including ruxolitinib [45].